What Is CJC-1295 (No DAC)?
CJC-1295 (No DAC) is a growth hormone secretagogue (ghrh analogue) supplied by Peptegrity for research and educational purposes. This page provides a factual educational overview of CJC-1295 (No DAC), including its classification, biological target, research background, terminology and published study context. It is not a product page and does not provide dosing instructions, treatment recommendations or personal-use guidance.
Type of compound
CJC-1295 (No DAC) is classified as a synthetic analogue of growth hormone-releasing hormone (GHRH). It acts as a growth hormone secretagogue, meaning it is designed to stimulate the secretion of growth hormone from the pituitary gland.
Biological target and mechanism
The compound functions by binding to and activating the GHRH receptor, mirroring the activity of endogenous GHRH. Research indicates that it promotes the release of growth hormone while maintaining the natural pulsatile pattern of secretion [2].
Research background
CJC-1295 was developed to improve the pharmacological profile of natural GHRH, which has a very short half-life in the body. Researchers study this analogue to understand its interactions with the neuroendocrine axis and its effects on growth hormone and insulin-like growth factor I (IGF-I) levels [1].
Current research and development status
CJC-1295 (No DAC) remains an investigational compound currently utilized exclusively for scientific research purposes. It has not been approved by the FDA or other regulatory agencies for human therapeutic use.
Published research context
Published studies have utilized this compound to examine the pharmacokinetics and pharmacodynamics of prolonged GHRH receptor stimulation [1]. Research has specifically investigated its influence on hormone profiles in healthy adult cohorts [1] and in clinical trial settings investigating metabolic states associated with HIV [3].
Relevant terminology
In this context, 'No DAC' refers to the absence of the Drug Affinity Complex, a chemical modification used in other versions to extend half-life. 'GHRH analogue' describes a synthetic substance engineered to mimic the structure and biological activity of naturally occurring growth hormone-releasing hormone.
Storage and handling terminology
Research peptides are typically stored as lyophilized powders in controlled environments, often at -20°C or lower to maintain stability. Proper laboratory protocols require reconstitution with appropriate sterile buffers before use to ensure consistency in experimental applications.
Testing and Certificate of Analysis (COA)
A Certificate of Analysis (COA) is a document issued by quality control laboratories that confirms the purity and identity of a chemical compound. Researchers should review these documents to verify that the specific batch has undergone testing, such as HPLC or Mass Spectrometry, to confirm its chemical profile.
Regulatory status
CJC-1295 (No DAC) is not an approved medication for any medical condition and is strictly intended for laboratory research and development. The sale and distribution of this substance are limited to authorized research entities and laboratories.
This page is for research and educational purposes only. It is not intended to provide medical advice, dosing instructions, or treatment recommendations, and does not represent any product as approved to diagnose, treat, cure or prevent any disease. Compounds described here may be investigational or unapproved medicines; regulatory status is summarised for information only.
Frequently asked questions
What is CJC-1295 (No DAC)?
CJC-1295 (No DAC) is a synthetic peptide analogue designed to function as a growth hormone secretagogue by interacting with the GHRH receptor.
How does CJC-1295 (No DAC) differ from the DAC-version?
The 'No DAC' variant lacks the Drug Affinity Complex, which differentiates its pharmacokinetic properties and clearance rate from the version that includes the complex.
What has research indicated about its effect on hormone secretion?
Studies have shown that it can stimulate the release of growth hormone and IGF-I while preserving the natural pulsatile secretion pattern [1, 2].
Is CJC-1295 (No DAC) approved for clinical use?
No, it is an investigational research compound that is not approved by regulatory bodies like the FDA for human therapeutic use.
What kind of studies have been conducted on this compound?
Research has included assessments of its physiological effects in healthy adults and investigative studies concerning individuals with specific metabolic challenges [1, 3].
References
- 1.Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsPubMed
- 2.Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analogPubMed
- 3.A Study to Evaluate CJC 1295 in HIV Patients With Visceral ObesityClinicalTrials.gov
